Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis

Thorax

Volumn 72, Issue 10, 2017, Pages 876-883

  Bos, L D ^a   Schouten, L R ^a   Van Vught, L A ^a   Wiewel, M A ^a   Ong, D S Y ^b   Cremer, O ^b   Artigas, A ^c   Martin Loeches, I ^d   Hoogendijk, A J ^a   Van Der Poll, T ^a   Horn, J ^a   Juffermans, N ^a   Calfee, C S ^e   Schultz, M J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ARDS; Cytokine Biology

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGPT1 PROTEIN, HUMAN; ANGPT2 PROTEIN, HUMAN; BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; BLOOD; CLUSTER ANALYSIS; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; MORTALITY; PHENOTYPE; PREDICTIVE VALUE; PROSPECTIVE STUDY;

AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOMARKERS; CLUSTER ANALYSIS; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MIDDLE AGED; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85030420621     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-209719     Document Type: Article

References (40)

1. Hudson LD, Steinberg KP. Epidemiology of acute lung injury and ARDS. Chest 1999;116:74S-82S.
2. Bersten AD, Edibam C, Hunt T, et al. Incidence and mortality of acute lung Injury and the Acute Respiratory Distress Syndrome in Three Australian States. Am J Respir Crit Care Med 2002;165:443-8.
3. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-93.
4. Gattinoni L, Haren F, Van Larsson A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315:788-800.
5. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest 2007;131:913-20.
6. Beitler JR, Schoenfeld DA, Thompson BT. Preventing ARDS: progress, promise, and pitfalls. Chest 2014;146:1102-13.
7. Takeda S, Ishizaka A, Fujino Y, et al. Time to change diagnostic criteria of ARDS: toward the disease entity-based subgrouping. Pulm Pharmacol Ther 2005;18:115-9.
8. Boyle AJ, McNamee JJ, McAuley DF. Biological therapies in the acute respiratory distress syndrome. Expert Opin Biol Ther 2014;14:969-81.
9. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 2006;21:119-43.
10. Matute-Bello G, Downey G, Moore BB, et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol 2011;44:725-38.
11. Ranieri VM, Rubenfeld GD, Thompson BT, et al., ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526-33.
12. Thille AW, Esteban A, Fernández-Segoviano P, et al. Comparison of the Berlin definition for acute respiratory distress syndrome with autopsy. Am J Respir Crit Care Med 2013;187:761-7.
13. Durham AL, Caramori G, Chung KF, et al. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res 2015;167:192-203.
14. Wood SL, Pernemalm M, Crosbie PA, et al. Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev 2015;41:361-75.
15. Agarwal R. Is the mortality higher in the pulmonary vs the extrapulmonary ARDS?. CHEST J 2008;133:1463.
16. Calfee CS, Janz DR, Bernard GR, et al. Distinct molecular phenotypes of direct versus indirect ARDS in single and multi-center studies. Chest 2015;147:1539-48.
17. Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2:611-20.
18. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776-87.
19. Schulzer M, Mancini GB. 'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol 1996;25:704-12.
20. WHO. Stratified medicine and pharmacogenomics. Prior Med Eur World Updat Rep 2013;4:1-5. http://www.who.int/medicines/areas/prioritymedicines/Ch74Stratified.pdf
21. Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017;195:331-8.
22. ARDS-Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301-8.
23. Putensen C, Theuerkauf N. Meta-analysis: ventilation Strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. Ann Intern Med 2013;151:566-76.
24. Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA 2010;303:865-73.
25. Hu SL, He HL, Pan C, et al. The effect of prone positioning on mortality in patients with acute respiratory distress syndrome: A meta-analysis of randomized controlled trials. Crit Care 2014;18:R109.
26. Wiedemann HP, Wheeler AP, Bernard GR, et al., National Heart and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564-75.
27. Minhas MA, Velasquez AG, Kaul A, et al. Effect of protocolized sedation on clinical outcomes in mechanically ventilated intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2015;90:613-23.
28. Geboers DGPJ, de Beer FM, Tuip-de Boer AMT, et al. Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients. Intensive Care Med 2015;41:1281-90.
29. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-24. http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&listuids=7509706
30. Charrad M, Ghazzali N, Boiteau V, et al. NbClust : an R Package for determining the relevant number of clusters in a data set. J Stat Softw 2014;61:1-36.
31. Zimmerman JE, Kramer AA, McNair DS, et al. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med 2006;34:1297-310.
32. Villar J, Ambrós A, Soler J, et al. Age, PaO2 /FIO2, and plateau pressure score: A proposal for a simple outcome score in patients with the acute respiratory distress syndrome. Crit Care Med 2016;44:1361-9.
33. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw 2011. http://doc.utwente.nl/78938/1/Buuren11mice.pdf (accessed 3 Oct 2014).
34. Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010;137:288-96.
35. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363:1107-16.
36. Agustí A, Antó JM, Auffray C, et al. Personalized respiratory medicine: Exploring the horizon, addressing the issues: Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. Am J Respir Crit Care Med 2015;191:391-401.
37. Sapru A, Calfee CS, Liu KD, et al. Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive Care Med 2015;41:470-8.
38. Nakamura T, Sato E, Fujiwara N, et al. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem 2011;44:601-4.
39. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005;33:319-27.
40. Prescott HC, Calfee CS, Thompson BT, et al. Towards smarter lumping and smarter splitting: rethinking strategies for Sepsis and ARDS Clinical Trial Design. Am J Respir Crit Care Med 2016;194:147-55.